BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 15630748)

  • 1. Mycophenolate mofetil induced myopathy in a patient with lupus nephritis.
    Galindo M; Cabello A; Joven B; Alonso A; Carreira P; Porta J; Ricoy JR; Mateo I; Pablos JL
    J Rheumatol; 2005 Jan; 32(1):188-90. PubMed ID: 15630748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
    Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
    J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lupus nephritis: treatment with mycophenolate mofetil.
    Kapitsinou PP; Boletis JN; Skopouli FN; Boki KA; Moutsopoulos HM
    Rheumatology (Oxford); 2004 Mar; 43(3):377-80. PubMed ID: 14963204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
    Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
    Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil.
    Flores-Suárez LF
    Arch Med Res; 2006 Jan; 37(1):68-73. PubMed ID: 16314189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.
    Glicklich D; Acharya A
    Am J Kidney Dis; 1998 Aug; 32(2):318-22. PubMed ID: 9708620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil for remission induction in severe lupus nephritis.
    Cross J; Dwomoa A; Andrews P; Burns A; Gordon C; Main J; Mathieson P; O'Donoghue D; Jayne D;
    Nephron Clin Pract; 2005; 100(3):c92-100. PubMed ID: 15824513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).
    Sinclair A; Appel G; Dooley MA; Ginzler E; Isenberg D; Jayne D; Wofsy D; Solomons N
    Lupus; 2007; 16(12):972-80. PubMed ID: 18042591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
    Sixdorf U; Bauer H; Märker-Hermann E
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil in lupus glomerulonephritis.
    Mok CC; Lai KN
    Am J Kidney Dis; 2002 Sep; 40(3):447-57. PubMed ID: 12200794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine.
    Fu YF; Liu GL
    Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
    Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of mycophenolate mofetil in the treatment of lupus nephritis.
    Grcevska L; Popovska MM; Dzikova S; Ristovska V; Polenakovic M
    Ann N Y Acad Sci; 2007 Sep; 1110():433-8. PubMed ID: 17911458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
    Zoja C; Benigni A; Noris M; Corna D; Casiraghi F; Pagnoncelli M; Rottoli D; Abbate M; Remuzzi G
    Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
    Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
    N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases.
    Kasitanon N; Petri M; Haas M; Magder LS; Fine DM
    Lupus; 2008 Jan; 17(1):40-5. PubMed ID: 18089682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rescue therapy in lupus nephritis patients with mycophenolate mofetil].
    Pretini VB; Avila López GE; Sesín AM; Dotto BH; Sanchez Freytes M; Sesín J; Vergottini JC
    Rev Fac Cien Med Univ Nac Cordoba; 2006; 63(3):39-46. PubMed ID: 17639816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for lupus nephritis.
    McCune WJ
    N Engl J Med; 2005 Nov; 353(21):2282-4. PubMed ID: 16306526
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
    Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.